In order to develop anti-CD123 CAR T cell therapy for AML, we first confirmed the expression of CD123 on primary human AML bone marrow (BM) versus healthy donor (HD) BM specimens (Supplementary Figs. 1 and 2a). This evidence concerns the gene IL3RA and acute myeloid leukemia.